Health Care • Biotechnology: Pharmaceutical Preparations
$4.77 ▲ +0.18
(+3.92%)
MKT CAP: $1.67B • VOL: 6.50M
52W L $4 52W H $10
NUVB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $62.9M | $7.9M | $0 |
| YoY Revenue Growth % | +699.0% | — | — |
| Gross Profit | — | $795.0K | — |
| Gross Margin % | — | 10.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$213.1M | -$592.6M | -$99.8M |
| Operating Margin % | -80.0% | -80.0% | — |
| Net Income (GAAP) | -$204.6M | -$567.9M | -$75.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$173.4M | -$130.4M | -$68.0M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$173.4M | -$130.4M | -$68.0M |
| FCF Margin % | -80.0% | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $164.1M | $35.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $305.7M | $463.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NUVB.